[1] EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012. 1: 167-185.
[2] Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine, 2012,12:2212-2219.
[3] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012,9859:2095-2128.
[4] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology, 2014,6:2099-2108.
[5] Wu X, Cai S, Li Z, et al. Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis. Virol J, 2016,1:64.
[6] Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther, 2012,11:1317-1325.
[7] Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Ann Intern Med, 2003,2:137-147.
[8] Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem, 2007,4:766-772.
[9] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet, 2012,9818:815-822.
[10] Stanifer JW, Muiru A, Jafar TH, et al. Chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant, 2016,6:868-874.
[11] Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol, 2011,6:1235-1240.
[12] Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology, 2009,3:727-734.
[13] Chen Y, Su Y, Li C, et al. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan. BMC Nephrol, 2015, 16:110.
[14] Piratvisuth T, Komolmit P, Tanwandee T, et al. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One, 2013,2:e54279.
[15] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 2003,9:800-807.
[16] Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat, 2012,10:732-743.
[17] Liang KH, Chen YC, Hsu CW, et al. Decrease of serum Angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates. Hepat Mon, 2014,1:e15074.
[18] Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med, 2008,23:2442-2455.
[19] Tsai MC, Chen CH, Tseng PL, et al. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect, 2016,1:91-95.
[20] Qi X, Wang JY, Mao RC, et al. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China. J Viral Hepat, 2015,1:46-54.
[21] Wang H, Hung C, Lee C, et al. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naive and-experienced chronic hepatitis B patients. J Gastroenterol Hepatol, 2016,31: 1307-1314.
[22] Shin JH, Kwon HJ, Jang HR, et al. Risk factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agents. Medicine (Baltimore), 2016,95:e2400.
[23] Lee S, Park JY, Song K, et al. Comparison of the effects of telbivudine and entecavir treatment on estimated glomerular filtration rate in patients with chronic hepatitis B. GutLiver, 2015,6:776.
[24] Gane EJ, Deray G, Liaw Y, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology, 2014,1:138-146.
[25] Gish RG, Clark MD, Kane SD, et al. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol, 2012,8:941-946, e68.
[26] Qi X, Wang J, Chen L, et al. Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B. Medicine (Baltimore), 2015,15:e646.
[27] Jiang L, Hu S, He M, et al. Estimated glomerular filtration rate increases in chronic hepatitis B patients treated with telbivudine monotherapy and combination treatment. Hepat Mon, 2016,16:e32528.
[28] Lee M, Oh S, Lee HJ, et al. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. J Viral Hepat, 2014,12:873-881. |
